News Quantified

TXMD – therapeuticsmd, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

TherapeuticsMD (NASDAQ:TXMD) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.

TherapeuticsMD (NASDAQ:TXMD) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.

TherapeuticsMD (NASDAQ:TXMD) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.

TherapeuticsMD (NASDAQ:TXMD) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Form 4 TherapeuticsMD, Inc. For: Dec 23 Filed by: Thompson Tommy G

Form 8-K TherapeuticsMD, Inc. For: Dec 15

Form 8-K TherapeuticsMD, Inc. For: Nov 12

Form 10-Q TherapeuticsMD, Inc. For: Sep 30

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Naughton Gail K

Top News Gainers

4/29 Form 10-K/A TherapeuticsMD, Inc. For: Dec 31 76.0%

3/24 TherapeuticsMD Strengthens Board with Appointment of Industry Leaders 21.6%

8/6 Q2/2019 6/30/2019 EPS -0.230 ZacksConsensus -0.170 ActVsEst (0.060) - Miss 20.9%

1/21 Form SC 13G/A TherapeuticsMD, Inc. Filed by: JPMORGAN CHASE & CO 20.6%

9/25 Form 8-K TherapeuticsMD, Inc. For: Sep 25 13.4%

2/5 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at Noble Financial. They now have a $13.00 price target on the stock. 11.7%

8/14 Form 4 TherapeuticsMD, Inc. For: Aug 12 Filed by: Milligan John C.K. IV 9.6%

12/23 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. 8.2%

9/16 Form 8-K TherapeuticsMD, Inc. For: Sep 16 7.9%

2/11 TherapeuticsMD: Inside The Numbers [Seeking Alpha] 6.6%

Top News Decliners

10/23 TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results -21.6%

6/11 TherapeuticsMD Inc (NASDAQ: TXMD) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $9.00 price target on the stock, down previously from $16.00. -20.9%

4/30 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -19.4%

5/6 Q1/2019 3/31/2019 EPS -0.160 ZacksConsensus -0.170 ActVsEst 0.010 - Beat -18.1%

3/26 TherapeuticsMD Provides COVID-19-Related Business Update -16.9%

3/16 TherapeuticsMD Provides Business Update on COVID-19 Pandemic -12.5%

8/13 Form 4 TherapeuticsMD, Inc. For: Aug 09 Filed by: Thompson Tommy G -11.9%

2/20 Q4/2019 12/31/2019 EPS -0.190 ZacksConsensus -0.200 ActVsEst 0.010 - Beat -11.2%

8/10 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.6%

12/2 TherapeuticsMD Inc (NASDAQ: TXMD) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -8.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day